DK36492D0 - PREPARATION - Google Patents

PREPARATION

Info

Publication number
DK36492D0
DK36492D0 DK92364A DK36492A DK36492D0 DK 36492 D0 DK36492 D0 DK 36492D0 DK 92364 A DK92364 A DK 92364A DK 36492 A DK36492 A DK 36492A DK 36492 D0 DK36492 D0 DK 36492D0
Authority
DK
Denmark
Prior art keywords
preparation
Prior art date
Application number
DK92364A
Other languages
Danish (da)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to DK92364A priority Critical patent/DK36492D0/en
Publication of DK36492D0 publication Critical patent/DK36492D0/en
Priority to AU38887/93A priority patent/AU3888793A/en
Priority to PCT/DK1993/000098 priority patent/WO1993018785A1/en
Priority to JP5516181A priority patent/JPH07504669A/en
Priority to EP93907819A priority patent/EP0631504A1/en
Priority to KR1019940703281A priority patent/KR950700754A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK92364A 1992-03-19 1992-03-19 PREPARATION DK36492D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (en) 1992-03-19 1992-03-19 PREPARATION
AU38887/93A AU3888793A (en) 1992-03-19 1993-03-18 Novel medicament
PCT/DK1993/000098 WO1993018785A1 (en) 1992-03-19 1993-03-18 Novel medicament
JP5516181A JPH07504669A (en) 1992-03-19 1993-03-18 new drug
EP93907819A EP0631504A1 (en) 1992-03-19 1993-03-18 Novel medicament
KR1019940703281A KR950700754A (en) 1992-03-19 1994-09-17 New drugs (NOVEL MEDICAMENT)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK92364A DK36492D0 (en) 1992-03-19 1992-03-19 PREPARATION

Publications (1)

Publication Number Publication Date
DK36492D0 true DK36492D0 (en) 1992-03-19

Family

ID=8092684

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92364A DK36492D0 (en) 1992-03-19 1992-03-19 PREPARATION

Country Status (6)

Country Link
EP (1) EP0631504A1 (en)
JP (1) JPH07504669A (en)
KR (1) KR950700754A (en)
AU (1) AU3888793A (en)
DK (1) DK36492D0 (en)
WO (1) WO1993018785A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
EP0646128A1 (en) * 1992-06-15 1995-04-05 Scios Inc. Glucagon-like peptide and insulinotropin derivatives
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
JP3149958B2 (en) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli Glp-1 formulations
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
ATE466026T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As DERIVATIVES OF GLP-1 AND EXENDIN WITH EXTENDED DURATION PROFILE
ATE466027T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As DERIVATIVES OF GLP-1 ANALOGUE
EP1306091A3 (en) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
EP1666054A1 (en) * 1998-08-28 2006-06-07 Eli Lilly & Company Method for administering insulinotropic peptides
HUP0103369A3 (en) * 1998-08-28 2002-03-28 Lilly Co Eli Use of insulinotropic peptides
WO2000037098A1 (en) * 1998-12-22 2000-06-29 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
JP2003519664A (en) * 2000-01-11 2003-06-24 ノボ ノルディスク アクティーゼルスカブ Transepithelial delivery of GLP-1 derivatives
ES2253353T3 (en) 2000-03-08 2006-06-01 Novo Nordisk A/S SERICO CHOLESTEROL REDUCTION.
DK1412384T3 (en) 2001-06-28 2008-04-28 Novo Nordisk As Stable formulation of modified GLP-1
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
BRPI0414539B8 (en) 2003-09-19 2021-05-25 Novo Nordisk As compound, pharmaceutical composition, and use of a compound
CN102784386A (en) 2003-11-20 2012-11-21 诺沃挪第克公司 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
AU2005303777B2 (en) 2004-11-12 2010-12-16 Novo Nordisk A/S Stable formulations of insulinotropic peptides
CN101128487B (en) 2004-12-02 2012-10-10 杜门蒂斯有限公司 Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
WO2007061434A2 (en) * 2005-11-10 2007-05-31 Nastech Pharmaceutical Company Inc. A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
BRPI0620586A2 (en) * 2005-12-02 2011-11-16 Nastech Pharm Co aqueous pharmaceutical formulation for intranasal administration and use of an aqueous pharmaceutical formulation to make a medicament
CN102046207B (en) 2008-03-31 2013-08-28 葛兰素集团有限公司 Drug fusions and conjugates
US8779103B2 (en) 2009-03-27 2014-07-15 Glaxo Group Limited Drug fusions and conjugates
AU2010303112A1 (en) 2009-09-30 2012-04-26 Glaxo Group Limited Drug fusions and conjugates with extended half life
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
US20150038417A1 (en) 2011-12-09 2015-02-05 Novo Nordisk A/S GLP-1 Agonists
GB201308753D0 (en) * 2013-05-15 2013-06-26 Stichting Nl Kanker Inst Compounds and their use in therapy
KR102665710B1 (en) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 GLP-1 composition and its uses
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
ATE138071T1 (en) * 1989-02-17 1996-06-15 Liposome Co Inc LIPID AIDS FOR ADMINISTRATION THROUGH THE NOSE AND TOPICAL APPLICATION
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
WO1991011457A1 (en) * 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment

Also Published As

Publication number Publication date
WO1993018785A1 (en) 1993-09-30
EP0631504A1 (en) 1995-01-04
KR950700754A (en) 1995-02-20
JPH07504669A (en) 1995-05-25
AU3888793A (en) 1993-10-21

Similar Documents

Publication Publication Date Title
DK36492D0 (en) PREPARATION
DE59303358D1 (en) Quaterrylenetetracarboximides
DE59306810D1 (en) Gutbettwalzenmühle
AT399443B (en) SPORTSHOE
BR9305745A (en) Lightbreaker
DE59301902D1 (en) CASHBOARD
DE59305364D1 (en) ROTORNUT
DE59304139D1 (en) POLYANILE
FIU920454U0 (en) Raeddningsanordning
ATA227792A (en) SPORTSHOE
BR9301712A (en) APLINATOR
DE59309200D1 (en) Bisphosphinoalkanes
DE59301762D1 (en) Chloroethylsulfonylbenzaldehydes
DK59092D0 (en) PREPARATION
DE59206388D1 (en) Kabeleckkanal
BR9204065A (en) Soprocopter
BR9203234A (en) SOFA-TABLE
FIU920437U0 (en) Skraptramsportoer
BR9204368A (en) Auto-collector
BR9204204A (en) Gabanto
BR9204074A (en) PRE-MOLDAN CONTRAMARCO
BR9202793A (en) PORTIMETER
BR9203563A (en) ROTORTRANCA
BR9203235A (en) COMPACTIMER
ATA256392A (en) BANDROOM

Legal Events

Date Code Title Description
ATS Application withdrawn